Results 141 to 150 of about 104,817 (211)

PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment

open access: yesCancer Science, EarlyView.
Graphical representation of formation of self‐assembled PEGylated Chitosan Nanoparticles and their mechanism in tumor localization. ABSTRACT Polymer‐based nanocarriers have emerged as transformative platforms in cancer nanomedicine, enabling controlled and site‐specific delivery of therapeutic agents.
Prashant Kesharwani   +5 more
wiley   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta   +12 more
wiley   +1 more source

Persistent in vitro nociceptor hyperexcitability and axonal retraction produced by repeated paclitaxel doses

open access: yesThe FEBS Journal, EarlyView.
Repeated paclitaxel exposure causes long‐lasting nociceptor hyperexcitability and axonal retraction in adult sensory neurons. Using a long‐term primary nociceptor culture, we show that hyperexcitability is mediated by sequential upregulation of NaV1.8, TRPV1, TRPA1, and TRPM8 channels.
Angela Lamberti   +3 more
wiley   +1 more source

Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment. [PDF]

open access: yesSupport Care Cancer
Zhou HY   +5 more
europepmc   +1 more source

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

open access: yesInternational Journal of Cancer, Volume 158, Issue 10, Page 2560-2570, 15 May 2026.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze   +19 more
wiley   +1 more source

PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment. [PDF]

open access: yesProc Natl Acad Sci U S A
Fang S   +15 more
europepmc   +1 more source

Body mass index and colorectal cancer recurrence and mortality: A nationwide cohort study in Denmark

open access: yesInternational Journal of Cancer, Volume 158, Issue 8, Page 2111-2119, 15 April 2026.
What's New? Obesity may worsen colorectal cancer prognosis, but the existing evidence remains inconclusive. This large nationwide cohort study comprehensively assessed how BMI interacts with demographic, clinical, and socioeconomic factors to influence colorectal cancer prognosis.
Cathrine F. Hjorth   +8 more
wiley   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy